At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Encaleretdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1
Calcilytix Therapeutics, Inc., a BridgeBio company·interventional·Posted Oct 9, 2020·Updated Nov 19, 2024
In Brief
A Phase 2 clinical trial evaluating Encaleret for Autosomal Dominant Hypocalcemia (ADH) and Autosomal Dominant Hypocalcemia Type 1 (ADH1). Completed, enrolled 13 participants across 1 site.
Detailed Summary
The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedOct 2020
Primary CompletionSep 2023
TodayJul 2026
First PostedOct 9, 2020
Enrollment StartSep 20, 2020
Primary CompletionSep 7, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.7 years ago
Interventions
Encaleretdrug
Tablets administered orally